Objectives For patients with multiple sclerosis (MS) with a high recurrence rate, treatment with disease-modifying drugs from the early stage is recommended. Although a decrease in brain volume has been reported in such patients, long-term and comparison studies with control participants have not been carried out in Japan. Methods Before this study, we built a cross-sectional brain image database of control participants. Among 73 patients with MS treated at Yokohama Rosai Hospital from April 2005 to April 2018, 34 MS patients who had been examined by 3T magnetic resonance scanner over a period of 4 years were enrolled in this study. We calculated the total intracranial volume of each patient, and the total brain volume, and gray and white matter volumes were adjusted by the total intracranial volume. We also examined the age, sex, disease-modifying drugs and type of MS. Results The brain volume of mild MS patients decreased with age at the same rate as that of control participants. However, the brain volume of all patients treated with fingolimod decreased faster than that of control participants. In some patients treated with interferon, the brain volume decreased faster than that of control participants. The brain volume of mild MS patients did not decrease more than that of control participants. Conclusions We could not determine the effect of fingolimod on brain volume decrease, because all patients treated with fingolimod were initially treated with interferon during the study period. The early administration of disease-modifying drugs is recommended from the perspective of minimizing decreases in brain volume.
Introduction
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that is characterized by multiple lesions in the brain, optic nerves and spinal cord. 1 Brain atrophy of patients with MS has been reported to be related to the progression of the disease. 2 A 2-year follow-up study of brain atrophy of patients with MS was reported, and similar rates of brain atrophy among the various types of MS was shown. 3 Although it was reported that the rate of brain volume decrease in Japanese MS patients was less than that of White people, a long-term study carried out for ≥4 years has not been reported in Japan. 4 In the present study, we investigated the progression of brain volume decrease in patients with MS compared with control participants over a period of 4 years in a clinical setting, using a magnetic resonance imaging (MRI) scanner.
Methods
Brain images of 8276 patients (4373 men, 3903 women) who were scanned using a 3T-MRI scanner (Verio or Skyra; Siemens Healthineers, Tokyo, Japan) at Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan, from 2008 to 2014, were collected. Images from patients aged 20-90 years who were scanned because of complaints of headaches or for the occurrence of cerebral concussion were included. MR images of patients who had stroke, contusion, alcoholism, neurological or psychological disorders and patients with subarachnoid cysts or cysts of the cavity of the septum pellucidum were excluded. Selected images from 140 male patients and 138 female patients were used in the present study. Their brain T1-weighted MR images (TR 2080 ms, TE 9.9 ms [Verio], 10 ms [Skyra] or TI 140 ms) were scanned in 5-mm thick slices with a 1-mm gap. Field of view was set to 220 mm, with a matrix size of 320 9 320 pixels. These images were used to establish a control database.
At Yokohama Rosai Hospital, 73 patients clinically diagnosed with MS using the McDonald criteria were treated from 2004 to 2018. 5 Among these patients, we investigated those who were scanned (T1-weighted images) in the clinic over a 4-year period. These images were obtained using similar 3T-MR scanners and the same sequence as for the control patients. We also recorded the patients' age at disease onset, age when first scanned and age at the final scan, as well as the subtype of MS, such as relapsing-remitting MS, secondary progressive MS (SPMS) or mild type. We defined the mild type of MS in patients with no relapse, no disease-modifying drugs, no MRI activity or no remarkable clinical change over 4 years. The MR images of patients in the relapsing phase were excluded in the present study.
Brain MR images of control patients were collected. In the construction of the database, each patient's brain MR image was anonymized and reconstructed to a 3-D image using NIH Image/J (http://rsb.info.nih. gov/nih-image). The coordinates of the anterior commissure were entered using Statistical Parametric Mapping 12 (https://www.fil.ion.ucl.ac.uk/spm/sof tware/spm12/) with Matlab (Mathworks, Natick, Massachusetts, USA), and segmented to gray matter (GM), white matter (WM) and cerebrospinal fluid (CSF) by "Diffeomorphic Anatomical Registration using Exponentiated Lie Algebra" (DARTEL) in Statistical Parametric Mapping 12, using T1.nii for the template image. Standard databases were then made for age groups, one every 10 years for ages 20-89 years.
We calculated the brain volume of segmented GM, WM and CSF of each control participant. We also calculated the whole brain volume (BV) as the sum of the GM and WM volumes. We adjusted the data points for intracranial volume (IV), which was the summated volume of GM, WM and CSF. Then, the ratios of BV to IV were determined. We named the ratio of BV to IV the BV index (BVI).
Next, we made a scatter plot of the BVI by age. As the rate of brain volume decrease can increase by age, the equation of the estimated BVI (eBVI) is suspected to be a quadratic function.
We analyzed both the BVI and eBVI using Solver with a non-linear solution in Microsoft Excel (Microsoft Corporation, Redmond, WA, USA). Then the Pearson correlation coefficient between BVI and eBVI was calculated.
The standard deviations (SD) and the averages of the BVI of each age group were calculated, and lines approximately two SD above and below the average of BVI of each age generation group were drawn.
Brain MR images of patients with MS were collected in a similar way using Statistical Parametric Mapping 12 with our control participants database for each age group as the standard database. We connected the dots of the BVI of each patient throughout the investigations.
We statistically investigated the slope of BVI of each patient and eBVI. As both group lines were estimated by quadratic functions, the square root of indexes was analyzed using the analysis of covariance (ANCOVA) method.
Ethics

Control patients
The imaging study of control patients was carried out in accordance with the Human Research Guidelines of the Institutional Ethical Review Board of Yokohama Rosai Hospital (approval number: 26-88). Consent was not required, but patients were informed via a website and notice boards.
MS patients
We studied the patients in accordance with the Human Research Guidelines from the Institutional Ethical Review Board of Yokohama Rosai Hospital (approval number: 30-18). Consent was not required, but patients were informed via a website and notice boards.
Results
We made a standard database for each sex separately and, as noted above, by age; one group for every 10 years, for the ages 20-89 years.
The estimating function and Pearson's correlation coefficients are shown below (eq. 5). The decrease ratios of male eBVI by group years were 0.236%, 0.236%, 0.236%, 0.236%, 0.237%, 0.237% and 0.237% in 20s, 30s, 40s, 50s, 60s, 70s and 80s, respectively. Those of female eBVI by group years were 0.160%, 0.180%, 0.202%, 0.222%, 0.243%, 0.264% and 0.285% in 20s, 30s, 40s, 50s, 60s, 70s and 80s, respectively (Fig. 1) .
A total of 34 patients with MS were enrolled in the present study (15 men, 19 women, W:M 1.27). The details of the patients are shown in Table 1 . The average onset age was 32.8 AE 9.27 years (SD), the first investigation age by 3T-MRI was 43.0 AE 9.30 years (SD) and the final investigation age was 48.5 AE 9.26 years (SD). The number of patients with each subtype was 28 with relapsing-remitting MS and six with SPMS. In the 28 patients with relapsingremitting MS, seven patients had mild MS.
Among all patients, six were treated with fingolimod, 15 with interferon, one with dimethyl fumarate, one with glatiramer acetate and prednisolone, four with nothing, two with phosphodiesterase inhibitor, and four with steroids. All the patients treated with fingolimod were converted to the medication from interferon. In the four patients treated with nothing, two patients were changed from interferon. The digit in parentheses shows the number of the patients whose brain volume decreased significantly faster than control participants. Figure 1 Brain volume of control participants (cross-sectional study). The brain volume of segmented gray matter, white matter and cerebrospinal fluid of each control participant were calculated. Brain volume resulted from summation of the volume of gray matter and white matter, and intracranial volume was calculated from the summation of gray matter, white matter and cerebrospinal fluid. The ratios of brain volume to intracranial volume were calculated and named as the brain volume index (BVI). The gray dots were estimating functions, and black dotted lines were AE2 SD lines.
In some patients with MS, the BVI decreased beyond the À2 SD line of the controls (Fig. 2) .
The brain volume of all six patients treated with fingolimod decreased significantly faster than that of control participants (Fig. 3) . In the 15 patients treated with interferons, the brain volume of six patients decreased significantly faster than that of the controls (Fig. 4) . The brain volume of mild MS patients tended to decrease with age at the same rate as that of the controls. Of the seven mild MS patients, the brain volume of one patient decreased faster than that of the controls (Fig. 5 ). In the six SPMS patients, the brain volume of five patients decreased faster than that of the controls (Fig. 6) . Details of the patient treatments by MS type are shown in Table 1 .
Discussion
To our knowledge, this is the first study to show cross-sectional brain shrinkage with age using MRI scans to calculate brain volume in Japanese control participants.
The shape of dotted lines in the plots created from patient data were not smooth, because we used 2-D MR images from clinical scans. This is a limitation of the present study, as 3-D T1-weighted images are recommended for evaluating brain volume. 8 However, with the 2-D images, we were able to observe the tendency of the brain volume to decline in clinical medical practice. In addition, we could detect the slope of the brain volume decline function based on a comparison with control participant data.
Akaishi et al. showed that the brain volume of Japanese MS patients tended to decrease at a slower rate than that of White patients. 4 This is consistent with the result of the present study, which showed that the brain volume in six of the seven mild MS patients did not decrease more than that of the controls. In addition, nine of the 15 patients treated with interferons also did not show a greater decrease in brain volume than the controls.
Unfortunately, we could not determine the effect of fingolimod on brain volume decrease in contrast to previous reports. 9, 10 We believe that the reason was that five of the six patients treated with fingolimod had been changed from interferon to fingolimod due to relapses during the observation period. We assume that interferon cannot inhibit the relapse and disease progression of MS, and that fingolimod cannot suppress the progression of brain atrophy in those patients.
In contrast to the significant brain volume decrease of five of the six SPMS patients, the brain volume of only one of the seven mild patients declined. Therefore, early and appropriate administration of diseasemodifying drugs is recommended from the point of view of minimizing decreases in brain volume.
In the present investigation, the brain volumes were standardized by intracranial brain volumes, similar to the method used in the Buckner study, and we named the standardized brain volume the brain volume index (BVI). 11 The shape of the dotted line of the BVI data is downward sloping, and is consistent with the shape of a quadratic function. In addition, the whole brain volume might continue to decrease year by year. Therefore, we used a quadratic decay function as the regression function similar to that used by Fotenos et al. and Takeda et al. 6, 7 The close correlation between the BVI and the eBVI supported this hypothesis.
The rate of eBVI decrease was slightly less than 0.237% per year in men, and 0.285% per year in women. These decrease rates are less than the 0.45% per year reported by Fotenos et al., in which the shrinkage rate of aging individuals was investigated in the brains of White people using MR imaging. 12 The decrease rate was also less than reported Figure 5 The brain volume index (BVI) of mild multiple sclerosis patients. The BVI of mild multiple sclerosis patients tended to decrease with age at the same rate as that of the control participants. In the seven mild multiple sclerosis patients, the BVI of one patient decreased faster than that of the controls. Figure 6 The brain volume index (BVI) of secondary progressive multiple sclerosis patients. In the six secondary progressive multiple sclerosis patients, the BVI of five patients decreased faster than that of the controls.
in the study by Takeda et al., in which the rate in healthy participants was reported as 0.33 AE 0.25% in people aged <65 years, and 0.53 AE 0.37% in people aged >65 years, using a computed tomography scanner. 6 The discrepancy of the rates is probably caused by the difference between the detectable areas of cerebrospinal fluid by MRI sequences or the computed tomography scanner, and might also be caused by the variation of participants between adult volunteers in the dementia research center in the USA and the admitted patients used as control participants in Japan. There is another report about brain shrinkage in aging from the same research group, but the authors did not discuss the shrinkage rate, and compared individuals aged in their 20s with individuals aged >65 years. 2 Another limitation of the present study was that, in contrast to a previous report, 13 we could not investigate the decrease rates of GM or WM volumes compared with those of controls. Therefore, further investigation is required.
There were some Japanese mild MS patients. From the perspective of minimizing decline in the brain volume of patients with MS, early and appropriate administration of disease-modifying drugs is recommended.
